

Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-Aug-2017  
Document Type: USP Monographs  
DocId: GUID-665DC0A6-C953-4FE1-B459-9BB0D05772B3\_2\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M34890\\_02\\_01](https://doi.org/10.31003/USPNF_M34890_02_01)  
DOI Ref: 7gwd4

© 2025 USPC  
Do not distribute

## Gentamicin Sulfate Ophthalmic Ointment

### DEFINITION

Gentamicin Sulfate Ophthalmic Ointment contains the equivalent of NLT 90.0% and NMT 135.0% of the labeled amount of gentamicin.

### IDENTIFICATION

#### • A. THIN-LAYER CHROMATOGRAPHY

**Standard solution:** 1 mg/mL of [USP Gentamicin Sulfate RS](#) in [water](#)

**Sample solution:** Nominally 1 mg/mL of gentamicin from Ophthalmic Ointment prepared as follows. Shake a quantity of Ophthalmic Ointment, containing nominally 5 mg of gentamicin, with a mixture of 200 mL of [chloroform](#) and 5 mL of [water](#). Allow to separate, and filter the aqueous layer.

#### Chromatographic system

(See [Chromatography \(621\)](#), [Thin-Layer Chromatography](#).)

**Adsorbent:** 0.25-mm layer of [chromatographic silica gel](#)

**Application volume:** 20  $\mu$ L

**Developing solvent system:** Mix [chloroform](#), [methanol](#), and [ammonium hydroxide](#) (20:13:10). Allow to separate, and use the lower layer.

#### Analysis

**Samples:** *Standard solution* and *Sample solution*

Apply the *Standard solution* and the *Sample solution* to the plate. Place the plate in a chromatographic chamber, and develop the chromatogram in the *Developing solvent system* until the solvent front has moved three-fourths of the length of the plate. Remove the plate, air-dry, and expose it to vapors of [iodine](#) in a detection jar containing iodine crystals.

**Acceptance criteria:** The intensities and  $R_f$  values of the three principal spots of the *Sample solution* correspond to those of the *Standard solution*.

### ASSAY

#### • PROCEDURE

(See [Antibiotics—Microbial Assays \(81\)](#).)

**Sample solution:** Shake a portion of Ophthalmic Ointment containing nominally 1 mg of gentamicin with about 50 mL of [ether](#) in a separator, and extract with four 20-mL portions of *Buffer B.3* (see the chapter). Combine the buffer extracts, and dilute with *Buffer B.3* to a suitable volume to obtain a *Test Dilution* with a gentamicin concentration that is nominally equivalent to the median level of the standard.

**Analysis:** Proceed as directed in the chapter.

**Acceptance criteria:** 90.0%–135.0%

### SPECIFIC TESTS

• **STERILITY TESTS (71):** Meets the requirements

• **OTHER REQUIREMENTS:** It meets the requirements for *Particulate and Foreign Matter* and *Container Contents* in [Ophthalmic Products—Quality Tests \(771\)](#), [Drug Product Quality, Universal Tests, Particulate and Foreign Matter](#) and [Container Contents](#).

### ADDITIONAL REQUIREMENTS

• **PACKAGING AND STORAGE:** Preserve in collapsible ophthalmic ointment tubes. Store at controlled room temperature.

• **USP REFERENCE STANDARDS (11)**

[USP Gentamicin Sulfate RS](#)

| Topic/Question                         | Contact   | Expert Committee                              |
|--|---|---|
| GENTAMICIN SULFATE OPHTHALMIC OINTMENT | <a href="#">Ying Han</a><br>Associate Science & Standards Liaison | BIO42020 Biologics Monographs 4 - Antibiotics |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 39(5)

Current DocID: GUID-665DC0A6-C953-4FE1-B459-9BB0D05772B3\_2\_en-US

Previous DocID: GUID-665DC0A6-C953-4FE1-B459-9BB0D05772B3\_1\_en-US

DOI: [https://doi.org/10.31003/USPNF\\_M34890\\_02\\_01](https://doi.org/10.31003/USPNF_M34890_02_01)

DOI ref: [Zgwd4](#)

OFFICIAL